Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL: FDG-PET/CT as biomarker of everolimus benefit in hormone-refractory postmenopausal breast cancer
2012-004860-22Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and exemestane in breast cancer, sponsored by Institut Jules Bordet. Primary endpoint: Proportion of FDG-PET/CT metabolic responders vs non-responders (pilot phase). Started Nov 2013; status: completed.
02
Drugs
everolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-004860-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004860-22.